Skip to main content
. 2017 Aug 5;1(2):202–215. doi: 10.1002/rth2.12029

Figure 5.

Figure 5

Effect of idarucizumab or placebo infusion on day 11 of coagulation variables, by dose group. Effect of idarucizumab (1, 2, 4, 2.5+2.5 g) and placebo on (A, B) diluted thrombin time (dTT), (C, D) ecarin clotting time (ECT), (E, F) activated partial thromboplastin time (aPTT), and (G, H) thrombin time (TT). bid, twice daily; DE, dabigatran etexilate